West Newton, MA, United States of America

Linda C Burkly

This inventor holds 23 USPTO granted patents and 17 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Biological Therapeutics. Top assignees: Biogen Idec Ma Inc., Biogen, Incorporated, Biogen Ma Inc.. Active years: 1999-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Linda C Burkly. Retrieved from https://idiyas.com/inventor/linda-c-burkly

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 17)

% Patents Active = 56.5

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 2.8

ph-index = 12

Forward Citations = 350(Granted Patents)

Company Filing History:

Albert Einstein College of Medicine

where one patent can have more than one assignee

Years Active: 1999-2017

Loading Chart...

Areas of Expertise:

Neurological Disorders

Lupus Nephritis

Binding Proteins

TWEAK-related Conditions

Inflammatory Bowel Disease

Tweak Binding Antibodies

Neovascularization

Common Gamma Chain

Anti-CD4 Antibodies

VLA-4 Blockers

Insulin Dependent Diabetes

Asthma

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9775899 - Treating neurological disorders (2017-10-03),

2. 9730947 - Method of treating lupus nephritis (2017-08-15),

3. 9321840 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2016-04-26),

4. 9011859 - Methods for treating TWEAK-related conditions (2015-04-21),

5. 8784823 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2014-07-22),

6. 8728475 - Methods for treating inflammatory bowel disease (2014-05-20),

7. 8506958 - Methods for treating TWEAK-related conditions (2013-08-13),

8. 8293237 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2012-10-23),

9. 8048635 - Measurement of soluble Tweak levels for evaluation of lupus patients (2011-11-01),

10. 8048422 - Tweak binding antibodies (2011-11-01),

11. 7731963 - TWEAK receptor agonists as anti-angiogenic agents (2010-06-08),

12. 7445778 - Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor (2008-11-04),

13. 7208151 - Tweak receptor agonists as anti-angiogenic agents (2007-04-24),

14. 7176184 - Treatment for inflammatory bowel disease with a fibronectin polypeptide (2007-02-13),

15. 6943146 - Method for promoting neovascularization (2005-09-13),

Title: Linda C Burkly: Pioneering Innovator in Neurological Disorder Treatments

Introduction:

Linda C Burkly, a highly accomplished inventor and researcher based in West Newton, MA, has made significant contributions to the field of neuroscience and the treatment of neurological disorders. With an impressive portfolio of 23 patents, Burkly has played a crucial role in advancing medical science, particularly in the areas of neuronal traumas and neurodegenerative disorders. This article explores Burkly's latest patents, career highlights, notable collaborations, and acknowledges her groundbreaking contributions to the healthcare industry.

Latest Patents:

Burkly's recent patents have revolutionized the treatment of neurological disorders. Her innovative methods involve utilizing TWEAK (tumor necrosis factor-like weak inducer of apoptosis) or TWEAK receptor blocking agents to address neuronal traumas and neurodegenerative disorders. These patents not only emphasize the importance of identifying specific molecules for therapeutic applications but also showcase Burkly's expertise in developing novel treatments for complex diseases.

1. Treating Neurological Disorders:

This patent focuses on novel methods for treating neuronal disorders, including mechanical neuronal traumas and neurodegenerative disorders. By utilizing TWEAK or TWEAK receptor blocking agents, Burkly's patents offer promising avenues for therapeutic interventions. These inventions have the potential to significantly improve the quality of life for individuals suffering from these conditions.

2. Method of Treating Lupus Nephritis:

Burkly's patents also feature methods for treating lupus nephritis. These inventions provide insights into evaluating patients for disease stage and severity to determine appropriate treatment options. By enhancing our understanding of lupus nephritis, this patent demonstrates Burkly's commitment to improving patient care and outcomes.

Career Highlights:

Throughout her career, Burkly has made substantial contributions in the biotechnology and medical sectors. Her exceptional work has garnered recognition and accolades within the scientific community. Burkly has worked with prestigious companies such as Biogen Idec MA Inc. and Biogen, Incorporated, where her expertise has been instrumental in driving breakthrough advancements in neurological disorder treatments.

Collaborations:

Burkly's collaborations with fellow researchers and scientists have played a pivotal role in the success of her innovative work. Notably, she has collaborated with Timothy Zheng and Aniela Jakubowski, esteemed professionals in the field. These collaborative efforts have fostered a collective pool of knowledge, inspiring new ideas and approaches to tackle complex medical challenges.

Conclusion:

Linda C Burkly's remarkable journey as an inventor and researcher demonstrates her unwavering commitment to advancing the field of neuroscience and improving patient outcomes. Through her patents and collaborations, Burkly has succeeded in revolutionizing the treatment of neurological disorders, with a particular focus on neuronal traumas and neurodegenerative disorders. Her ingenuity and dedication firmly establish her as a trailblazer in the healthcare industry, leaving a lasting impact on the lives of countless individuals worldwide.

Profile summary based on public USPTO records.